If you liked this article you might like

Mylan EpiPen Scrutiny Puts More Biotechs at Risk
Stocks Ride the Flatline in Choppy Trade Ahead of Yellen Speech
Mylan to Offer Savings Card on EpiPen After Controversial 400% Price Increase
Mylan's Mistake: Making Money?